TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).
Rachel A. Freedman(Dana-Farber Cancer Institute), Nancy U. Lin(Dana-Farber Cancer Institute), Julie R. Nangia(Unknown), Carey K. Anders(Duke University), Beverly Moy(Global Cancer Institute), Antonio C. Wolff(Johns Hopkins University), Minetta C. Liu(Mayo Clinic), Ian E. Krop(Yale Cancer Center), Sarah Farooq(Dana-Farber Cancer Institute), Catherine Van Poznak(University of Michigan), Polly Niravath(Houston Methodist), Nadine Tung(Beth Israel Deaconess Medical Center), Rebecca Gelman(Dana-Farber Cancer Institute), Eric P. Winer(University of Vermont), Christine M. Cotter(Dana-Farber Cancer Institute), Anne B. Cropp(Pfizer (United States)), Kimberly Blackwell(Duke University), Michelle Melisko(University of California, San Francisco), Shannon Puhalla(UPMC Hillman Cancer Center), Roisín M. Connolly(Johns Hopkins University)
Cited by 36
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
The Seattle Heart Failure Model
|Circulation|2006|2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k